Early RA Referral Clinics Work!
An outcomes study from the Leiden Early Arthritis Clinic (EAC) has shown substantially less diagnostic delay and better long-term outcomes when patients are referred to EAC compared to usual referrals.
Read Article
EBR Journal Club: Dapirolizumab Pegol in SLE (PHOENYCS GO)
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. Each review covers four domains: Does this apply to my patients? What is the risk https://t.co/Pi45T99oJm
Dr. John Cush @RheumNow( View Tweet )
AI Diagnosing Rheumatic Disease?
Prof. Valmed, a large language model (LLM) cleared by European regulators for medical diagnosis, outperformed human physicians for diagnosing rheumatologic conditions in terms of speed but not accuracy, a randomized trial showed. https://t.co/WVKlRGHFL1
Dr. John Cush @RheumNow( View Tweet )
Weight Loss Improves Psoriatic Disease Substantially!
Even before the introduction of incretin therapy and bariatric surgery, many randomized and interventional studies (2019–2026) have consistently showed that weight loss produces clinically meaningful, dose-dependent improvement in both psoriasis and psoriatic arthritis.
Read Article
A Day of Infamy (9.11.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis. And take this week's RheumIQ quiz
Read Article
RCT 451 chronic LBP in general practice shows 8-wk telehealth mindfulness reduced pain intensity and interference at 6 months compared with usual care, BUT changes did not meet the prespecified mean 1-point MCID between groups. Is it worth doing? https://t.co/H4oYTeq1is https://t.co/cozq7gGnYO
Dr. John Cush @RheumNow( View Tweet )
JAMA: Review of Adult Rheumatoid Arthritis
Smolen, Kerschbaumer, Aletaha, and Robinson have published a comprehensive review article of rheumatoid arthritis (RA) in JAMA, noting significant changes to our understanding and treatment guidelines.
Read Article
Physician SURVEY> When prescribing a generic, where do you refer the Patient?
Dr. John Cush @RheumNow( View Tweet )
ACP Position Statements on the Ethics of AI in Medical Practice
Recently JAMA updated its guidance on artificial intelligence (AI) in medical publications. Now, the ACP has published a position paper regarding the use and ethical considerations for the use of AI in medical https://t.co/J6qgfI2Sgt
Dr. John Cush @RheumNow( View Tweet )
AI Diagnosing Rheumatic Disease?
MedPage Today
Prof. Valmed, a large language model (LLM) cleared by European regulators for medical diagnosis, outperformed human physicians for diagnosing rheumatologic conditions in terms of speed but not accuracy, a randomized trial showed.
Read Article
ACP Position Statements on the Ethics of AI in Medical Practice
Recently JAMA updated its guidance on artificial intelligence (AI) in medical publications. Now, the ACP has published a position paper regarding the use and ethical considerations for the use of AI in medical practice.
Read Article
Treating Obesity is Disease-Modifying (9.4.2026)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. New drugs approved, new drugs halted and some drugs out of control. Ready to test your knowlege? Take this week's quiz!
Read Article
BMI Affects JAK Inhibitor Responses in Rheumatoid Arthritis
A meta-analysis of Janus kinase (JAKi) inhibitors clinical trials in rheumatoid arthritis (RA) has shown higher BMI was associated with poorer responses and a reduced treatment benefit with JAK inhibitors in RA patients.
Read Article
Music and Pain Relief
If laughter is the best medicine, then music has to be second best. A new scoping review in Pain Reports by Bradt et al., examines the effect of music-based interventions (MBIs) on pain management. While its efficacy is well established, how or why music relieves pain has never been fully
Read Article
“ABCDE” Approach to Difficult-to-Treat Rheumatoid Arthritis
The proposed approach to difficult-to-treat rheumatoid arthritis is based on the EULAR definition (having failed 2 or more b/tsDMARDs). The authors provide guidance in the form of an easy acronym, A B C D E, which covers both diagnostic and therapeutic considerations.
Read Article
Novartis & BMS CAR-T Cell Trials on Hold
Reuters and the Wall Street Journal report that both Novartis and Bristol Myers Squibb (BMS) have paused their autoimmune disease CAR-
Read Article
Rheums! Do you have a Rheumatology question or case for Dr. Cush? Record it here, and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/LZ59KW8HdA https://t.co/DwHdvpTYax
Dr. John Cush @RheumNow( View Tweet )
EUSTAR Registry - Cancer in Systemic Sclerosis
Cancer is a major cause of mortality in systemic sclerosis (SSc). A nested case-control study within EUSTAR registry shows distinct patterns of cancer related temporally to SSc, serologic profiles and traditional cancer risk factors.
Cancers were
FDA Approves Brepocitinib to Treat Dermatomyositis
The FDA and Priovant recently annouced approval of brepocitinib (Lisraya), a JAK1/TYK2 inhibitor, for the indication of adults with dermatomyositis (DM). This is the first oral (once daily) agent approved for DM.
Read Article
NME: New Molecular Entities (8.28.2026)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!
Read Article
Secukinumab in Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a common disorder of the elderly that responds well to glucocorticoids (GC), but is plagued by an inability to wean off of GCs.
Insights into Sjögren’s Disease - A Rheum Survey
RheumNow recentlty surveyed rheumatologists about Sjogren’s disease (SjD) - how they approach diagnosis, treatment, and unique challenges; all important as new advances in SjD evolves.
Read Article
Brepocitinib Skin Outcomes in Patients With Dermatomyositis
A secondary analysis of the VALOR trial has shown that the TYK2/JAK1 inhibitor brepocitinib was effective at cutaneous disease activity outcomes, delivering rapid, clinically meaningful, and remission-level control of cutaneous dermatomyositis (DM).
Read Article
JAMA Review: Postural Orthostatic Tachycardia Syndrome (POTS)
Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance.
Read Article
Rheum Scholarship (8.21.2026)
Dr. Cush reviews the news and journal articles from this past week on RheumNow; talking about lumbar belts, scholarships and misdiagnosis.
https://t.co/T6uggKb8n7 https://t.co/HJCMQqghaE
Dr. John Cush @RheumNow( View Tweet )
Therapeutic Updates
Lupus Nephritis
Sponsored by RheumNow
View our six video perspectives on lupus nephritis, including Management of CKD in Lupus Nephritis.
Read Post
Women in Rheumatology: Gender Issues in Disease and Management
Sponsored by Bristol Myers Squibb
Nine videos discussing gender differences in axSpA, PsA, Vasculitis, Lung Disease, Osteoporosis, Disparities in Healthcare, and Rheumatologic Activity and Treatment, are now available.
Read Post
Recent Blogs
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Better Gout Management
